Small Molecules

26 Jan 2017 Phase III trial of anticancer agent Lenvima® as first-line treatment for unresectable hepatocellular carcinoma meets primary endpoint
25 Jan 2017 Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
25 Jan 2017 BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenström’s Macroglobulinemia
25 Jan 2017 4SC AG: Overall survival benefit for resminostat in first-line liver cancer study subgroup
25 Jan 2017 European Medicines Agency Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie's Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
23 Jan 2017 Sanifit Announces Enrollment of First Patient in CaLIPSO – a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialsis
23 Jan 2017 Actelion announces results of the MAESTRO study with macitentan in patients with pulmonary arterial hypertension due to Eisenmenger Syndrome
21 Jan 2017 ChemoCentryx Announces Presentation of Data from Ongoing Phase Ib Clinical Trial of CCR2 Inhibitor CCX872 in Patients with Advanced Non-Resectable Pancreatic Cancer
21 Jan 2017 Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
21 Jan 2017 European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
21 Jan 2017 Infinity Presents Preclinical Data and Phase 1 Clinical Data on IPI-549 at PI3K Keystone Symposia Conference
19 Jan 2017 Allergan Announces FDA Approval Of RHOFADE™ (Oxymetazoline Hydrochloride) Cream, 1% For The Topical Treatment Of Persistent Facial Erythema Associated With Rosacea In Adults
19 Jan 2017 U.S. FDA Approves IMBRUVICA® (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
19 Jan 2017 Ezra Announces FDA Acceptance Of Filing Of New Drug Application For EZR-104 For The Treatment Of Hypertension And Heart Failure
18 Jan 2017 Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study
18 Jan 2017 Teva Receives FDA Approval for VANTRELATM ER (Hydrocodone Bitartrate) Extended-Release Tablets [CII] Formulated with Proprietary Abuse Deterrence Technology
18 Jan 2017 Psyadon Announces Positive Results from Phase 2b Clinical Study of Ecopipam for the Treatment of Tourette’s Syndrome in Children
18 Jan 2017 Neurocrine Announces Completion of Phase II Clinical Study of VMAT2 Inhibitor INGREZZA™ (valbenazine) in Adults with Tourette Syndrome
18 Jan 2017 Alcobra Reports Phase 3 Clinical Trial of MDX in Adults with ADHD Missed Primary Endpoint
17 Jan 2017 Allergan and Gedeon Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
16 Jan 2017 Chi-Med Initiates a Phase II Combination Study of Fruquintinib with Iressa® (gefitinib) in First-Line Non-Small Cell Lung Cancer
16 Jan 2017 Chi-Med Initiates a Phase II Study of Sulfatinib in Second-line Biliary Tract Cancer in China
14 Jan 2017 ObsEva Announces Completion of Phase 1 First-in-Women Study of OBE022 for the Treatment of Preterm Labor
14 Jan 2017 Heron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)
14 Jan 2017 Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing